UCB SA (OTCMKTS:UCBJF) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of UCB SA (OTCMKTS:UCBJF) have received a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company.

Separately, Piper Sandler reiterated a “neutral” rating on shares of UCB in a report on Wednesday.

UCB Stock Down 2.3%

Shares of UCB stock opened at $277.44 on Wednesday. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. UCB has a 52-week low of $200.21 and a 52-week high of $345.39. The company has a 50-day simple moving average of $292.79 and a two-hundred day simple moving average of $300.88.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.